Glenmark receives IND application clearance to begin Phase I trial of GBR 1302-BEAT for HER2+ cancer
The US Food and Drug Administration (FDA) has cleared pharmaceutical company Glenmark ’s investigational new drug (IND) application to begin a phase I trial of GBR 1302-BEAT to treat HER2+ cancers.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | HER2 | Investigational New Drugs | Pharmaceuticals